Hlib Chabaniuk

Phathom Pharmaceuticals calls for greater EoE research to address daily life impact in U.S.

Phathom Pharmaceuticals calls for greater EoE research to address daily life impact in U.S.
Phathom drives EoE research efforts

Eosinophilic esophagitis (EoE) impacts approximately one in 2,000 people in the U.S., posing significant challenges to daily life.

Phathom Pharmaceuticals is leveraging #EoEDay to advocate for increased research and awareness of EoE. The company points to the ongoing need for clinical advancements and invites the public to learn more about its current clinical trial dedicated to addressing this condition.

Phathom Pharmaceuticals recently participated in the ThinkDHC patient engagement webinar, where SVP Nancy Phelan spoke on point-of-care marketing strategies at the event. The company is also set to present new clinical efficacy and safety data for VOQUEZNA during a live session at the upcoming DDW2026 conference according to an earlier announcement. These actions highlight the firm's ongoing focus on both patient engagement and clinical research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.